AtriCure
AtriCure Inc is an American medical technology company specializing in the development, manufacture, and distribution of innovative surgical ablation systems, left atrial appendage management devices, and pain management solutions used primarily by cardiothoracic surgeons to treat atrial fibrillation and related cardiac disorders. The company designs and produces advanced radiofrequency ablation clamps, cryoablation devices, and exclusion systems utilized in open-heart and minimally invasive surgical procedures globally. Its core operations encompass biomedical device engineering, surgical instrument manufacturing, clinical education, and global wholesale distribution. Revenue is derived directly from the global wholesale sale of single-use surgical ablation devices and implantable medical equipment to hospitals and surgical centers. AtriCure holds a leading global market position in surgical treatment devices for atrial fibrillation. The company is headquartered in Mason, Ohio, United States, and its common stock trades on the Nasdaq Global Select Market.
5 of the funds FundTelligence covers report a position in AtriCure.
- Legal name
- AtriCure Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
Funds holding AtriCure
- BNP Health Care Innovators — BNP Paribas · 0.6 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 0.58 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.29 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)